NASDAQ:OMED - Oncomed Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.88 -0.02 (-2.21 %) (As of 03/22/2019 04:00 PM ET)Previous Close$0.8835Today's Range$0.8502 - $0.923852-Week Range$0.55 - $3.45Volume132,808 shsAverage Volume476,374 shsMarket Capitalization$34.18 millionP/E Ratio-5.52Dividend YieldN/ABeta1.81 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California. Receive OMED News and Ratings via Email Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OMED Previous Symbol CUSIPN/A CIK1302573 Webwww.oncomed.com Phone650-995-8200Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio5.04Price-To-Earnings Trailing P/E Ratio-5.52 Forward P/E Ratio-0.88 P/E GrowthN/A Sales & Book Value Annual Sales$44.42 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book0.71Profitability EPS (Most Recent Fiscal Year)($0.16) Net Income$-8,100,000.00 Net Margins-18.24% Return on Equity-13.14% Return on Assets-7.73%Miscellaneous Employees22 Outstanding Shares38,690,000Market Cap$34.18 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions What is Oncomed Pharmaceuticals' stock symbol? Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED." How were Oncomed Pharmaceuticals' earnings last quarter? Oncomed Pharmaceuticals Inc (NASDAQ:OMED) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative return on equity of 13.14% and a negative net margin of 18.24%. View Oncomed Pharmaceuticals' Earnings History. When is Oncomed Pharmaceuticals' next earnings date? Oncomed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Oncomed Pharmaceuticals. What price target have analysts set for OMED? 2 brokerages have issued 1-year price targets for Oncomed Pharmaceuticals' stock. Their predictions range from $1.50 to $2.00. On average, they anticipate Oncomed Pharmaceuticals' share price to reach $1.75 in the next year. This suggests a possible upside of 98.1% from the stock's current price. View Analyst Price Targets for Oncomed Pharmaceuticals. What is the consensus analysts' recommendation for Oncomed Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncomed Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncomed Pharmaceuticals. Has Oncomed Pharmaceuticals been receiving favorable news coverage? News coverage about OMED stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Oncomed Pharmaceuticals' key competitors? Some companies that are related to Oncomed Pharmaceuticals include China SXT Pharmaceuticals (SXTC), Eton Pharmaceuticals (ETON), Chiasma (CHMA), Harrow Health (HROW), Unum Therapeutics (UMRX), Sol Gel Technologies (SLGL), Zynerba Pharmaceuticals (ZYNE), Syndax Pharmaceuticals (SNDX), Imprimis Pharmaceuticals (IMMY), Correvio Pharma (CORV), DURECT (DRRX), XOMA (XOMA), Corvus Pharmaceuticals (CRVS), Selecta Biosciences (SELB) and Fortress Biotech (FBIO). What other stocks do shareholders of Oncomed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncomed Pharmaceuticals investors own include Verastem (VSTM), Celldex Therapeutics (CLDX), Clovis Oncology (CLVS), Portola Pharmaceuticals (PTLA), Melinta Therapeutics (MLNT), GW Pharmaceuticals PLC- (GWPH), NewLink Genetics (NLNK), Novavax (NVAX), Exelixis (EXEL) and Tetraphase Pharmaceuticals (TTPH). Who are Oncomed Pharmaceuticals' key executives? Oncomed Pharmaceuticals' management team includes the folowing people: Mr. Perry A. Karsen, Exec. Chairman (Age 64)Dr. John A. Lewicki, Pres, CEO & Director (Age 67)Dr. Robert Stagg, Sr. VP of Clinical R&D (Age 60)Ms. Yvonne Li, VP of Fin. & Admin. and Controller (Age 59)Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality Assurance Who are Oncomed Pharmaceuticals' major shareholders? Oncomed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include HarbourVest Partners LLC (4.92%), Perceptive Advisors LLC (4.45%), BlackRock Inc. (0.59%), Acadian Asset Management LLC (0.51%), Norges Bank (0.47%) and Geode Capital Management LLC (0.45%). Company insiders that own Oncomed Pharmaceuticals stock include Alicia J Hager, Austin Gurney, Jack W Lasersohn, John A Lewicki, Jonathan D Root, Paul J Hastings, Perry A Karsen, Sunil Patel and Yvonne Li. View Institutional Ownership Trends for Oncomed Pharmaceuticals. Which major investors are selling Oncomed Pharmaceuticals stock? OMED stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, D. E. Shaw & Co. Inc. and BlackRock Inc.. Company insiders that have sold Oncomed Pharmaceuticals company stock in the last year include Alicia J Hager, Austin Gurney, John A Lewicki and Yvonne Li. View Insider Buying and Selling for Oncomed Pharmaceuticals. Which major investors are buying Oncomed Pharmaceuticals stock? OMED stock was acquired by a variety of institutional investors in the last quarter, including HarbourVest Partners LLC, Norges Bank, Birchview Capital LP, Geode Capital Management LLC, Geode Capital Management LLC and Acadian Asset Management LLC. Company insiders that have bought Oncomed Pharmaceuticals stock in the last two years include Jack W Lasersohn and Perry A Karsen. View Insider Buying and Selling for Oncomed Pharmaceuticals. How do I buy shares of Oncomed Pharmaceuticals? Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oncomed Pharmaceuticals' stock price today? One share of OMED stock can currently be purchased for approximately $0.8835. How big of a company is Oncomed Pharmaceuticals? Oncomed Pharmaceuticals has a market capitalization of $34.18 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe. What is Oncomed Pharmaceuticals' official website? The official website for Oncomed Pharmaceuticals is http://www.oncomed.com. How can I contact Oncomed Pharmaceuticals? Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected] MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 268 (Vote Outperform)Underperform Votes: 233 (Vote Underperform)Total Votes: 501MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Why Invest in Dividend Achievers?